FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102590541> ?p ?o ?g. }

• W2102590541 endingPage "1074" @default.
• W2102590541 startingPage "1067" @default.
• W2102590541 abstract "Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. This randomized, placebo-controlled phase III study assessed the efficacy of vandetanib plus pemetrexed as second-line therapy in advanced non-small-cell lung cancer.Patients (N = 534) were randomly assigned to receive vandetanib 100 mg/d plus pemetrexed 500 mg/m(2) every 21 days (n = 256) or placebo plus pemetrexed (n = 278). Progression-free survival (PFS) was the primary end point; overall survival, objective response rate, disease control rate, time to deterioration of symptoms, and safety were secondary assessments.There was no significant difference in PFS between treatment arms (hazard ratio [HR], 0.86; 97.58% CI, 0.69 to 1.06; P = .108). Overall survival was also not significantly different (HR, 0.86; 97.54% CI, 0.65 to 1.13; P = .219). Statistically significant improvements in objective response rate (19% v 8%; P < .001) and time to deterioration of symptoms (HR, 0.71; P = .0052; median, 18.1 weeks for vandetanib and 12.1 weeks for placebo) were observed in patients receiving vandetanib. Adding vandetanib to pemetrexed increased the incidence of some adverse events, including rash, diarrhea, and hypertension, while showing a reduced incidence of nausea, vomiting, anemia, fatigue, and asthenia with no reduction in the dose intensity of pemetrexed.This study did not meet the primary end point of statistically significant PFS prolongation with vandetanib plus pemetrexed versus placebo plus pemetrexed. The vandetanib combination showed a significantly higher objective response rate and a significant delay in the time to worsening of lung cancer symptoms versus the placebo arm as well as an acceptable safety profile in this patient population." @default.
• W2102590541 created "2016-06-24" @default.
• W2102590541 creator A5003664573 @default.
• W2102590541 creator A5007609170 @default.
• W2102590541 creator A5008880845 @default.
• W2102590541 creator A5010872796 @default.
• W2102590541 creator A5021704329 @default.
• W2102590541 creator A5023551823 @default.
• W2102590541 creator A5025511599 @default.
• W2102590541 creator A5035063101 @default.
• W2102590541 creator A5039952118 @default.
• W2102590541 creator A5052962058 @default.
• W2102590541 creator A5053909240 @default.
• W2102590541 creator A5070000852 @default.
• W2102590541 creator A5074179223 @default.
• W2102590541 creator A5089954905 @default.
• W2102590541 date "2011-03-10" @default.
• W2102590541 modified "2023-10-14" @default.
• W2102590541 title "Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial" @default.
• W2102590541 cites W1839238860 @default.
• W2102590541 cites W2004350020 @default.
• W2102590541 cites W2011797387 @default.
• W2102590541 cites W2025084353 @default.
• W2102590541 cites W2033048942 @default.
• W2102590541 cites W2038861931 @default.
• W2102590541 cites W2062316437 @default.
• W2102590541 cites W2078765085 @default.
• W2102590541 cites W2082122438 @default.
• W2102590541 cites W2099725888 @default.
• W2102590541 cites W2107666024 @default.
• W2102590541 cites W2109833554 @default.
• W2102590541 cites W2110835998 @default.
• W2102590541 cites W2111060860 @default.
• W2102590541 cites W2112621029 @default.
• W2102590541 cites W2114940128 @default.
• W2102590541 cites W2115078104 @default.
• W2102590541 cites W2120031407 @default.
• W2102590541 cites W2120718661 @default.
• W2102590541 cites W2122553809 @default.
• W2102590541 cites W2123230605 @default.
• W2102590541 cites W2125212831 @default.
• W2102590541 cites W2126655764 @default.
• W2102590541 cites W2127101185 @default.
• W2102590541 cites W2127809030 @default.
• W2102590541 cites W2130652363 @default.
• W2102590541 cites W2133232813 @default.
• W2102590541 cites W2134667653 @default.
• W2102590541 cites W2138297714 @default.
• W2102590541 cites W2145835533 @default.
• W2102590541 cites W2146404049 @default.
• W2102590541 cites W2150335765 @default.
• W2102590541 cites W2152755651 @default.
• W2102590541 cites W2161245591 @default.
• W2102590541 cites W2162724777 @default.
• W2102590541 cites W86651134 @default.
• W2102590541 doi "https://doi.org/10.1200/jco.2010.29.5717" @default.
• W2102590541 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21282537" @default.
• W2102590541 hasPublicationYear "2011" @default.
• W2102590541 type Work @default.
• W2102590541 sameAs 2102590541 @default.
• W2102590541 citedByCount "258" @default.
• W2102590541 countsByYear W21025905412012 @default.
• W2102590541 countsByYear W21025905412013 @default.
• W2102590541 countsByYear W21025905412014 @default.
• W2102590541 countsByYear W21025905412015 @default.
• W2102590541 countsByYear W21025905412016 @default.
• W2102590541 countsByYear W21025905412017 @default.
• W2102590541 countsByYear W21025905412018 @default.
• W2102590541 countsByYear W21025905412019 @default.
• W2102590541 countsByYear W21025905412020 @default.
• W2102590541 countsByYear W21025905412021 @default.
• W2102590541 countsByYear W21025905412022 @default.
• W2102590541 countsByYear W21025905412023 @default.
• W2102590541 crossrefType "journal-article" @default.
• W2102590541 hasAuthorship W2102590541A5003664573 @default.
• W2102590541 hasAuthorship W2102590541A5007609170 @default.
• W2102590541 hasAuthorship W2102590541A5008880845 @default.
• W2102590541 hasAuthorship W2102590541A5010872796 @default.
• W2102590541 hasAuthorship W2102590541A5021704329 @default.
• W2102590541 hasAuthorship W2102590541A5023551823 @default.
• W2102590541 hasAuthorship W2102590541A5025511599 @default.
• W2102590541 hasAuthorship W2102590541A5035063101 @default.
• W2102590541 hasAuthorship W2102590541A5039952118 @default.
• W2102590541 hasAuthorship W2102590541A5052962058 @default.
• W2102590541 hasAuthorship W2102590541A5053909240 @default.
• W2102590541 hasAuthorship W2102590541A5070000852 @default.
• W2102590541 hasAuthorship W2102590541A5074179223 @default.
• W2102590541 hasAuthorship W2102590541A5089954905 @default.
• W2102590541 hasConcept C126322002 @default.
• W2102590541 hasConcept C142724271 @default.
• W2102590541 hasConcept C143998085 @default.
• W2102590541 hasConcept C168563851 @default.
• W2102590541 hasConcept C170493617 @default.
• W2102590541 hasConcept C197934379 @default.
• W2102590541 hasConcept C203092338 @default.
• W2102590541 hasConcept C204787440 @default.
• W2102590541 hasConcept C27081682 @default.
• W2102590541 hasConcept C2776694085 @default.

• next